Abiopharma

(99% Neutral) Lyra Therapeutics Inc (LYRA) Announces Clinical Development Update

(10% Negative) Alnylam Pharmaceuticals Inc (ALNY) Announces Delay in leadership Trials for AMVUTTRA Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

(10% Negative) TScan Therapeutics Inc. (TCRX) Files Form 8-K

Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

EDAP Announces Preliminary Record Fourth Quarter and Full Year 2025 HIFU Revenue; Issues 2026 Revenue Guidance

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

Kiniksa Pharmaceuticals Provides Corporate Update

XOMA Royalty Announces CFO Transition

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

XOMA Royalty Announces CFO Transition

iRhythm Technologies, Inc. Shares Preliminary Fourth Quarter 2025 Highlights and Business Update at the 44th Annual J.P. Morgan Healthcare Conference

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

(90% Positive) Corbus Pharmaceuticals Holdings Inc. (CRBP) Files Form 8-K